相关实验视频

Updated: Sep 16, 2025

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

衍生伊萨丁化:合成,结构,血小板造影,抗血小板和抗凝活动评估

Aleksandr V Samorodov¹, Wang Yi², Dmitry A Kudlay^3,4

¹Department of Pharmacology, Bashkir State Medical University, Lenin St. 3, Ufa 450008, Russia.

International journal of molecular sciences

|July 12, 2025

概括

合成了新的含的伊萨丁化,并显示出有前途的抗聚合活性. 这些化合物有效抑制血小板激活,为开发新型抗血栓药物提供了潜力.

科学领域:

药用化学医学化学
有机合成有机合成
药理学药理学是指药理学的学科.

背景情况:

血小板聚合是血栓形成的关键因素.
开发具有提高疗效的新型抗聚合剂药物至关重要.
伊萨衍生物和有机化合物已经显示出生物活性.

研究的目的:

用含的部分合成新型的伊萨丁.
评估这些化合物的抗聚合剂和抗血小板激活特性.
研究合成化合物的结构和立体化学方面.

主要方法:

通过氧化物或酸盐化物与基替代的酸盐的反应合成异酸.
使用31P NMR和X射线晶体学进行表征.
使用乙撒利酸作为参考对抗聚合剂活性的评估.
在组织因子 (TF) 激活的血小板激活抑制 (TEG) 和ex vivo血栓形成模型中的血小板激活抑制的评估.

主要成果:

成功合成了新的含的伊萨丁.
使用31P NMR在溶液中的空间异构体比率 (1:1到 1:3) 的确定.
通过量子化学计算和X射线分析确认气体,溶液和晶体状态中占主导地位的Z,syn形式.
氧化物衍生物和特定的酸盐类型显示出与酸相比的抗聚合活性.
在TF-激活的TEG和ex vivo血栓形成模型中,5-酸衍生物显示出优异的抗聚合作用.

结论:

合成的伊萨丁酸具有显著的抗凝聚剂和抗血小板激活特性.
Z,syn同位素是主要和稳定的形式.
这些化合物有潜力开发具有广泛抗血栓应用的先进抗聚合药物.

关键词:

它具有抗血栓活性.晶体结构晶体结构血液静止血液静止血液静止化的含量是多少化这就是伊萨酸.是一种的物质.

更多相关视频

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

Preparation of Quality Inositol Pyrophosphates

Preparation of Quality Inositol Pyrophosphates

Published on: September 3, 2011

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Phosphoinositides and PIPs

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...